23andMe Goes Global In Its Data-Mining Efforts
By Megan Molteni,
Wired
| 05. 18. 2018
Yanny or Laurel—could the secret to which word you hear be in your DNA? It’s a notion someone pitched at 23andMe headquarters Thursday, during the consumer genetics outfit’s annual Genome Research Day. (Spoiler: The company is not going to roll out a survey to see if the latest meme has a genetic component.)
The event—a sort of cross between a science fair and a recruiting booth—attracted more than 100 researchers to the company’s candy cane–colored lunchroom for a day of talks, poster presentations, and most importantly, information sessions about how to work with 23andMe’s consumer data riches.
23andMe has amassed more than 4 million genetic profiles from customers who’ve consented to be studied, one of the biggest genetic research resources in the US. And because most of those people fill out lots of surveys, each genetic profile comes attached to about 300 phenotypic data points—like how many cigarettes you’ve smoked during your lifetime or if anyone in your family has ever been diagnosed with mild cognitive impairment.
And while the company has doubled in size over the last two years...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...
